Quince Therapeutics, Inc.
Quince Therapeutics, Inc. (QNCX): 2 pipeline candidates · ~8 mo cash runway · 2 clinical trials. Updated within the last hour.
BioSniper Score
5-factor signal · derived from public data
8.0 months
D/E 0.70 · 0% dilution
Lead: Phase 3
2 candidates
N/A
0 buys · 1 sell (180d)
A transparent, data-derived signal for Quince Therapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
$17.7M
Cash
$18.2M
Quarterly Burn
$7.6M
Runway
8.0 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (2 candidates)
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
6
Total value held
$27K
| Holder | Shares | Value |
|---|---|---|
| tudor investment corp et al | 220,000 | $22K |
| gen-wealth partners inc | 33,018 | $3K |
| fortitude family office, llc | 8,095 | $821 |
| advisory services network, llc | 5,500 | $558 |
| parallel advisors, llc | 795 | $81 |
| sbi securities co., ltd. | 135 | $14 |
Frequently asked questions
How many drug candidates are in Quince Therapeutics, Inc.'s pipeline?
Quince Therapeutics, Inc. (QNCX) has 2 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Quince Therapeutics, Inc.'s lead drug candidate?
Quince Therapeutics, Inc.'s most advanced tracked candidate is edsp (Phase 3) for Duchenne muscular dystrophy (DMD).
What is Quince Therapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Quince Therapeutics, Inc. has approximately 8.0 months of cash runway.
What is Quince Therapeutics, Inc.'s market capitalization?
Quince Therapeutics, Inc.'s market capitalization is approximately $17.7M.
Who is the CEO of Quince Therapeutics, Inc.?
Dr. Dirk Thye M.D. is the chief executive officer of Quince Therapeutics, Inc. (QNCX).
Get the full picture on Quince Therapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.